Abstract
| Safety and efficacy of parenteral iron in children with inflammatory bowel disease Papadopoulos M1, Patel D2, Korologou-Linden R3, Goto E1, Soondrum K1, Fell JME1, Epstein J1. Br J Clin Pharmacol. 2017 Dec 20. doi: 10.1111/bcp.13493. [Epub ahead of print] |
| Author information 1 Department of Paediatric Gastroenterology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH. 2 Department of Paediatric Pharmacy, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH. 3 Faculty of Medicine, St Mary's Campus, Imperial College, Praed Street, London, W2 1PG. Abstract OBJECTIVES: Iron deficiency anaemia (IDA) frequently complicates inflammatory bowel disease (IBD) in children and adults. Oral iron may exacerbate gastrointestinal symptoms and absorption may be insufficient in intestinal inflammation. Even where oral iron is successful, repletion of iron stores can be unacceptably slow. Intravenous (IV) iron compounds were in the past associated with serious adverse reactions and historically were considered a last resort in children. New generation preparations have a safer profile in adults although reluctance to use them in children may persist, where safety data is lacking. We investigate the safety and efficacy of ferric carboxymaltose (FCM) and iron sucrose (IS) in children. METHODS: We retrospectively identified all children with IBD who received parenteral iron over a 38 month period in a single regional referral centre. Safety, tolerability and adverse events were established by case note review. Efficacy was assessed by change in haematinic indices pre- and post-treatment. RESULTS: 41 children (18 male; median age 14yrs, range 3-17) received a total of 104 iron infusions. 44% (18) had Crohn's disease (CD); 56% (23) ulcerative colitis (UC). 35 received FC, seven IS and one both. Three children developed mild rash post infusion which resolved quickly with chlorphenamine. Mean increase in haemoglobin (Hb) was 2.5g/dl (0.3-5.8). Iron levels increased by a mean of 8.4 g/dl (1-25), transferrin saturation by 16.2% (2-47). Transferrin decreased by 0.84 g/dl (0.3-3.4). CONCLUSIONS: New generation parenteral iron preparations are safe, well tolerated and efficacious in children with IDA and IBD. |
© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only.
Use of this website is governed by the GIHF terms of use and privacy statement.
